FDA Peptide Reclassification 2026 Amanecia Health The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica